Try
Cytokinetics Incorporated Common Stock
CYTKUnited States
25 filed reports · 313 financial concepts · 1 earnings calls · 4 media appearances
Filed reports
25 reports · Sep 2020 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 2 guidance figures.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 17 | 2,186 | Mar 2021 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 6 | 2,436 | Dec 2020 to Dec 2025 |
| Current · 8-KSEC EDGAR | 1 | 2 | Dec 2020 |
| Quarterly · 10-Q/ASEC EDGAR | 1 | 1 | Sep 2020 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 6, 2026 | 285 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 5, 2026 | 158 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 26, 2026 | 735 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 5, 2025 | 194 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 7, 2025 | 100 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 6, 2025 | 99 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Feb 27, 2025 | 385 | Open |
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Nov 7, 2024 | 127 | Open |
| FY2024 Q2 | 10-Q | Jun 30, 2024 | Aug 9, 2024 | 100 | Open |
| FY2024 Q1 | 10-Q | Mar 31, 2024 | May 10, 2024 | 100 | Open |
| FY2023 | 10-K | Dec 31, 2023 | Feb 28, 2024 | 337 | Open |
| FY2023 Q3 | 10-Q | Sep 30, 2023 | Nov 3, 2023 | 115 | Open |
Financial data
313 concepts · 4,625 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial311 concepts · 4,505 facts · Dec 2018 to Aug 2026
- Cash cash equivalents restricted cash and restricted cash equivalents including disposal group and discontinued operations36 · Dec 2018 to Jun 2026
- Stockholders equity (US GAAP)36 · Dec 2018 to Jun 2026
- Convertible notes, net35 · Dec 2019 to Jun 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value34 · Dec 2018 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect34 · Dec 2018 to Jun 2026
- Comprehensive income net of tax34 · Dec 2018 to Jun 2026
- Depreciation depletion and amortization34 · Dec 2018 to Jun 2026
- Increase decrease in accounts payable trade34 · Dec 2018 to Jun 2026
- Increase decrease in accounts receivable34 · Dec 2018 to Jun 2026
- Increase decrease in accrued liabilities34 · Dec 2018 to Jun 2026
- Interest receivable and amortization on investments34 · Dec 2018 to Jun 2026
- Net cash provided by used in financing activities34 · Dec 2018 to Jun 2026
- Net cash provided by used in investing activities34 · Dec 2018 to Jun 2026
- Net cash provided by used in operating activities34 · Dec 2018 to Jun 2026
- Net income loss34 · Dec 2018 to Jun 2026
- Nonoperating income expense34 · Dec 2018 to Jun 2026
- Operating expenses (US GAAP)34 · Dec 2018 to Jun 2026
- Operating income loss34 · Dec 2018 to Jun 2026
- Operating lease liabilities34 · Dec 2018 to Jun 2026
- Other comprehensive income loss available for sale securities adjustment net of tax34 · Dec 2018 to Jun 2026
- Payments to acquire available for sale securities debt34 · Dec 2018 to Jun 2026
- Payments to acquire property plant and equipment34 · Dec 2018 to Jun 2026
- Proceeds from maturities prepayments and calls of available for sale securities34 · Dec 2018 to Jun 2026
- Profit loss34 · Dec 2018 to Jun 2026
Product1 concepts · 118 facts · Dec 2018 to Jun 2026
- Revenue118 · Dec 2018 to Jun 2026
Guidance1 concepts · 2 facts · Feb 2021
- Revenue Guidance2 · Feb 2021
Segments
118 factsFigures broken down by business line, region, product or another axis the company reports on.
Product or service8 members · 118 facts
- Research And Development25 · Dec 2018 to Sep 2024
- Collaboration Revenues24 · Dec 2022 to Jun 2026
- Milestone19 · Dec 2018 to Sep 2024
- License And Milestone Revenues14 · Dec 2021 to Jun 2026
- Realization Of Revenue Participation Right Purchase Agreement14 · Dec 2020 to Dec 2024
- License12 · Dec 2018 to Dec 2023
- Milestones6 · Sep 2020 to Sep 2021
- Net Product Revenue4 · Mar 2025 to Jun 2026
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
- Earnings-release commentary81 claims from 7 reports · Dec 2024 to Jun 2026
- Management discussion (MD&A) commentary165 claims from 8 reports · Sep 2024 to Jun 2026
- Risk-factor changes19 claims from 1 reports · Dec 2025
- Risk factors77 risks from 2 annual reports · 2024 to 2025
Earnings calls
1 calls · Aug 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Aug 6, 2026
Executive media
4 appearancesPodcasts, interviews and conference appearances by the company's executives, with their claims.
- TV interviews3 · Mar 2023 to Oct 2025
- Other appearances1 · Mar 2025
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.